Orahelp is a topical pain-relief medication that contains choline salicylate (8.5 %) and lignocaine (2 %). It is supplied in a bottle for external application to the skin. The product is classified under pain management and skin-care categories and is regulated in Hong Kong by the Department of Health under the Pharmacy and Poisons Ordinance.
These indications are consistent with the approved uses for topical NSAID-plus-local-anaesthetic products in Hong Kong.
These are usually self-limiting and resolve with reduced frequency of application or discontinuation.
Routine laboratory monitoring is not required for short-term topical use. Patients should observe the treated skin for signs of worsening irritation or allergic reaction and seek medical advice if these occur.
This article provides educational information about Orahelp and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Orahelp is intended for localized application. Applying it to extensive body surfaces can increase systemic absorption and the risk of toxicity. Limit use to the specific painful area and follow the recommended frequency.
The formulation contains 8.5 % choline salicylate and 2 % lignocaine by weight/volume. This concentration provides both anti-inflammatory and local-anaesthetic actions in a single product.
Orahelp is classified as a non-prescription topical analgesic in Hong Kong and can be purchased at pharmacies without a physician’s prescription, provided the buyer is 18 years or older.
Orahelp combines lidocaine (lignocaine) with an NSAID, offering both numbing and anti-inflammatory benefits. Plain lidocaine gel provides only the anaesthetic effect and does not address inflammation.
Applying Orahelp prior to light activity can reduce discomfort, but avoid excessive use or occlusion during intense exercise, as sweating may increase skin absorption.
The formulation includes standard preservatives to maintain stability, but the specific agents are listed on the product label. Patients with known sensitivities should review the label carefully.
Tolerance is unlikely with short-term topical use. Prolonged daily application over months should be discussed with a healthcare professional to assess efficacy and safety.
Topical NSAIDs are generally discouraged during the first trimester. Pregnant individuals should consult their obstetrician before using Orahelp, especially if regular use is anticipated.
Discontinue the product immediately, gently wash the area with mild soap and water, and seek medical advice to determine whether an allergic reaction has occurred.
Orahelp is not approved for pediatric use under the age of 12 years. If pain relief is needed for a child, a healthcare professional should recommend an age-appropriate alternative.